The shadow of generic competition has repeatedly loomed over copyright’s famous drug, PDE5 Inhibitor, triggering questions about the future of connected pharmaceutical stakes. While first times saw substantial gains, the intellectual property end has created the door for discounted substitutes, possibly reducing profitability and posing a signifi